ALAdam J. Langer

Adam J. Langer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam J. Langer has a total of 144 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    1651. Describing the Tuberculosis Infection Cascade of Care Based on Electronic Health Record Data

    by Laura A Vonnahme, Jonathan Todd, Jon Puro, Jee Oakley, Matthew Jones, Pedro Rivera, Adam J Langer, Tracy Ayers

    Appropriate screening of individuals to detect latent tuberculosis infection (LTBI) is a critical step for achieving tuberculosis (TB) elimination in the US; >80% of TB cases are attributed to LTBI reactivation. TB infection testing and treatment must engage community health clinics where populations at risk seek care. However, there are significant data knowledge gaps in the current LTBI cascade of care (CoC) in this setting. We used an electronic health record (EHR) database from OCHIN, Inc., to characterize the LTBI CoC and identify potential future interventions. We extracted a cohort of patients from 2012–2016 EHR data; we stratified by whether patients were at risk for TB based on meeting at least one of the following criteria: non-US born or non-English language preference, homelessness, encounter at correctional facility, history of close contact with a TB case, or being immunocompromised. Along each step of the LTBI CoC, we determined the proportions with a test for TB infection, with available test results, with a positive test, with an LTBI diagnosis, and with LTBI treatment prescribed. We used Χ 2 tests to compare the LTBI CoCs among patients at risk with those classified as not at risk. Of nearly 2.2 million patient records, 701,467 (32.0%) met criteria for being at risk for TB; 84,422 at risk (12.0%) were tested; 65,562 (77.7%) had available results, of whom 9,624 (14.7%) were positive. Among those with positive results, 6,958 (72.3%) had an LTBI diagnosis, of whom 1,732 (24.9%) were prescribed treatment. Among those classified as not at risk, fewer were tested (66,773 [4.5%], p< 0.001) and had positive results (2,500 [3.7%], p< 0.0001). Among those with positive results, 1,998 (80.0%) had an LTBI diagnosis, of whom 395 (19.8%) initiated treatment. This study highlights gaps in the LTBI CoC, and where interventions are most needed. The largest gaps were in testing patients at risk, as 88% were not tested, and treatment, as 75% diagnosed with LTBI were not treated. Just under half (44%) of all TB tests appeared to be performed in persons with little risk for TB; this is a substantial amount of testing given very few begin treatment. Resources could be redirected to increase screening and treatment among populations at risk. All Authors: No reported disclosures

  • Open Access

    Association Between Birth Region and Time to Tuberculosis Diagnosis After US Entry Among Non–US-Born Persons

    by Amish Talwar, Rongxia Li, Adam J. Langer

    Approximately 90% of US tuberculosis (TB) cases among non–US-born persons are attributable to progression of latent TB infection to TB disease. Using survival analysis, we investigated if birthplace is associated with time of progression to TB disease among non–US-born persons. We derived a Cox regression model comparing differences in time to TB diagnosis after US entry among 19 global birth regions, adjusting for sex, birth year, and age at diagnosis. Compared with persons from Western Europe, the adjusted hazard rate of developing TB was significantly higher (p ≤0.05) for persons from all other regions, except North America and Northern Europe, and highest among persons from Middle Africa (adjusted hazard ratio = 7.0; 95% confidence interval: 6.5–7.4). Time to TB diagnosis among non–US-born persons therefore varied by birth region, which represents an important prognostic indicator for progression to TB disease.

  • Open Access

    Tuberculosis — United States, 2019

    by Noah G. Schwartz, Sandy F. Price, Robert H. Pratt, Adam J. Langer

    Progress towards eliminating tuberculosis (TB) in the United States has slowed, underscoring the need to ramp up TB prevention efforts.


  • Open Access

    US Tuberculosis Rates among Persons Born Outside the United States Compared with Rates in Their Countries of Birth, 2012–20161

    by Clarisse A. Tsang, Adam J. Langer, J. Steve Kammerer, Thomas R. Navin

    The US Centers for Disease Control and Prevention recommends screening populations at increased risk for tuberculosis (TB), including persons born in countries with high TB rates. This approach assumes that TB risk for expatriates living in the United States is representative of TB risk in their countries of birth. We compared US TB rates by country of birth with corresponding country rates by calculating incidence rate ratios (IRRs) (World Health Organization rate/US rate). The median IRR was 5.4. The median IRR was 0.5 for persons who received a TB diagnosis <1 year after US entry, 4.9 at 1 to 10 years. Our analysis suggests that World Health Organization TB rates are not representative of TB risk among expatriates in the United States and that TB testing prioritization in the United States might better be based on US rates by country of birth and years in the United States.


  • Epidemiology of Tuberculosis in the United States

    by Adam J. Langer, Thomas R. Navin, Carla A. Winston, Philip LoBue


  • Noncountable Tuberculosis Case Reporting, National Tuberculosis Surveillance System, United States, 2010-2014

    by Robert H. Pratt, Lilia P. Manangan, Charisse Nitura Cummings, Adam J. Langer

    Objectives: Supplemental federal funding is allocated to state and local tuberculosis (TB) programs using a formula that considers only countable cases reported to the National Tuberculosis Surveillance System (NTSS). Health departments submit reports of cases, which are countable unless another (US or international) jurisdiction has already counted the case or the case represents a recurrence of TB diagnosed ≤12 months after completion of treatment for a previous TB episode. Noncountable cases are a resource burden, so in 2009, NTSS began accepting noncountable case reports as an indicator of program burden. We sought to describe the volume and completeness of noncountable case reports. Methods: We analyzed 2010-2014 NTSS data to determine the number and distribution of noncountable cases reported. We also surveyed jurisdictions to determine the completeness of noncountable case reporting and obtain information on jurisdictions’ experience in reporting noncountable cases. In addition, we prepared a hypothetical recalculation of the funding formula to evaluate the effect of including noncountable cases on funding allocations. Results: Of 54 067 TB case reports analyzed, 1720 (3.2%) were noncountable; 47 of 60 (78.3%) jurisdictions reported ≥1 noncountable case. Of 60 programs surveyed, 34 (56.7%) responded. Of the 34 programs that responded, 24 (70.6%) had not reported all their noncountable cases to NTSS, and 11 (32.4%) stated that reporting noncountable cases was overly burdensome, considering the cases were not funded. Conclusions: Complete data on noncountable TB cases help support estimates of programmatic burden. Ongoing training and a streamlined reporting system to NTSS can facilitate noncountable case reporting.


  • Open Access

    Changes in tuberculosis epidemiology, United States, 1993–2017

    by L. R. Armstrong, C. A. Winston, B. Stewart, C. A. Tsang, A. J. Langer, T. R. Navin

    BACKGROUND: After 20 years of steady decline, the pace of decline of tuberculosis (TB) incidence in the United States has slowed. METHODS: Trends in TB incidence rates and case counts since 1993 were assessed using national US surveillance data. Patient characteristics reported during 2014–2017 were compared with those for 2010–2013. RESULTS: TB rates and case counts slowed to an annual decline of respectively 2.2% (95%CI −3.4 to −1.0) and 1.5% (95%CI −2.7 to −0.3) since 2012, with decreases among US-born persons and no change among non-US-born persons. Overall, persons with TB diagnosed during 2014–2017 were older, more likely to have combined pulmonary and extra-pulmonary disease than extra-pulmonary disease alone, more likely to be of non-White race, and less likely to have human immunodeficiency virus infection, or cavitary pulmonary disease. During 2014–2017, non-US-born persons with TB were more likely to have diabetes mellitus, while the US-born were more likely to have smear-positive TB and use non-injecting drugs. CONCLUSION: Changes in epidemiologic trends are likely to affect TB incidence in the coming decades. The Centers for Disease Control and Prevention has called for increased attention to TB prevention through the detection and treatment of latent tuberculous infection.


  • Open Access

    Tuberculosis — United States, 2018

    by Amish Talwar, Clarisse A. Tsang, Sandy F. Price, Robert H. Pratt, William L. Walker, Kristine M. Schmit, Adam J. Langer


  • Open Access

    Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004–2015

    by Zimy Wansaula, Jonathan M. Wortham, Godwin Mindra, Maryam B. Haddad, Jorge L. Salinas, David Ashkin, Sapna B. Morris, Gail B. Grant, Smita Ghosh, Adam J. Langer

    BCG Cases Reported to TB Surveillance, USA


  • Open Access

    Tuberculosis — United States, 2017

    by Rebekah J. Stewart, Clarisse A. Tsang, Robert H. Pratt, Sandy F. Price, Adam J. Langer

    In 2017, the tuberculosis (TB) provisional case count and rate were the lowest in the United States since national TB surveillance began in 1953; however, the rate in 2017 (2.8 per 100,000) is still 28 times the U.S. elimination threshold of one case per 1 million persons.